 David Kroll
Concepts (447)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Topoisomerases, Type II | 11 | 2005 | 45 | 1.360 |
Why?
| | Antineoplastic Agents, Phytogenic | 16 | 2012 | 190 | 1.120 |
Why?
| | Plant Extracts | 10 | 2010 | 202 | 0.800 |
Why?
| | Silymarin | 10 | 2016 | 199 | 0.740 |
Why?
| | Phytotherapy | 8 | 2010 | 83 | 0.670 |
Why?
| | Isoenzymes | 5 | 2001 | 304 | 0.610 |
Why?
| | Plants, Medicinal | 7 | 2009 | 22 | 0.530 |
Why?
| | Antineoplastic Agents | 13 | 2016 | 2123 | 0.520 |
Why?
| | Prostatic Neoplasms | 10 | 2016 | 1034 | 0.490 |
Why?
| | Topoisomerase II Inhibitors | 3 | 2005 | 25 | 0.420 |
Why?
| | Flavonolignans | 4 | 2009 | 10 | 0.410 |
Why?
| | Camptothecin | 4 | 2009 | 115 | 0.410 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 839 | 0.410 |
Why?
| | Hypocreales | 4 | 2013 | 8 | 0.400 |
Why?
| | Drug Interactions | 5 | 2010 | 406 | 0.390 |
Why?
| | Etoposide | 3 | 2001 | 158 | 0.380 |
Why?
| | Hypericum | 2 | 2001 | 2 | 0.380 |
Why?
| | Drug Screening Assays, Antitumor | 16 | 2013 | 195 | 0.370 |
Why?
| | Tumor Cells, Cultured | 9 | 2006 | 953 | 0.350 |
Why?
| | Transcriptional Activation | 4 | 1997 | 378 | 0.340 |
Why?
| | DNA | 9 | 2001 | 1458 | 0.290 |
Why?
| | Molecular Structure | 15 | 2013 | 489 | 0.290 |
Why?
| | Paclitaxel | 2 | 2009 | 227 | 0.270 |
Why?
| | Anti-Bacterial Agents | 6 | 2013 | 1796 | 0.260 |
Why?
| | Biological Products | 3 | 2012 | 215 | 0.260 |
Why?
| | Cell Line, Tumor | 19 | 2016 | 3406 | 0.250 |
Why?
| | Promoter Regions, Genetic | 4 | 2005 | 1249 | 0.250 |
Why?
| | Terminology as Topic | 1 | 2007 | 216 | 0.240 |
Why?
| | Plant Proteins | 2 | 2004 | 113 | 0.220 |
Why?
| | Antigens, Neoplasm | 6 | 2005 | 319 | 0.220 |
Why?
| | DNA-Binding Proteins | 6 | 2005 | 1501 | 0.220 |
Why?
| | Colchicum | 3 | 2010 | 3 | 0.210 |
Why?
| | Butyrates | 2 | 2001 | 61 | 0.200 |
Why?
| | Peptaibols | 2 | 2013 | 2 | 0.200 |
Why?
| | Terphenyl Compounds | 2 | 2013 | 4 | 0.200 |
Why?
| | Indole Alkaloids | 2 | 2012 | 7 | 0.200 |
Why?
| | Sesquiterpenes | 2 | 2013 | 55 | 0.190 |
Why?
| | Transfection | 5 | 2000 | 941 | 0.190 |
Why?
| | Antifungal Agents | 2 | 2013 | 136 | 0.190 |
Why?
| | Herbal Medicine | 1 | 2001 | 4 | 0.190 |
Why?
| | Perylene | 1 | 2001 | 9 | 0.190 |
Why?
| | Terpenes | 1 | 2001 | 22 | 0.190 |
Why?
| | Mixed Function Oxygenases | 1 | 2001 | 40 | 0.180 |
Why?
| | Benzene | 1 | 2001 | 18 | 0.180 |
Why?
| | Thylakoids | 1 | 2001 | 5 | 0.180 |
Why?
| | Drug Carriers | 3 | 1998 | 127 | 0.180 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 48 | 0.180 |
Why?
| | Hemostasis | 1 | 2001 | 82 | 0.180 |
Why?
| | Genes, Plant | 1 | 2001 | 50 | 0.180 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 155 | 0.180 |
Why?
| | Gene Expression Regulation, Enzymologic | 3 | 2008 | 283 | 0.170 |
Why?
| | Antioxidants | 4 | 2016 | 584 | 0.170 |
Why?
| | Biomedical Research | 1 | 2007 | 688 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2012 | 2051 | 0.170 |
Why?
| | Arabidopsis Proteins | 1 | 2001 | 75 | 0.170 |
Why?
| | NF-kappa B | 4 | 2012 | 691 | 0.170 |
Why?
| | Arabidopsis | 1 | 2001 | 95 | 0.160 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2001 | 210 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2004 | 559 | 0.160 |
Why?
| | Liposomes | 2 | 1998 | 220 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2016 | 437 | 0.160 |
Why?
| | Neoplasms | 4 | 2009 | 2643 | 0.160 |
Why?
| | Ericales | 1 | 1999 | 2 | 0.160 |
Why?
| | Diterpenes | 3 | 2009 | 31 | 0.160 |
Why?
| | Theophylline | 1 | 1999 | 67 | 0.150 |
Why?
| | Cell Cycle Proteins | 3 | 2008 | 613 | 0.150 |
Why?
| | Magnoliopsida | 1 | 1998 | 33 | 0.150 |
Why?
| | Humans | 55 | 2016 | 136750 | 0.150 |
Why?
| | Annonaceae | 2 | 2009 | 4 | 0.140 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 8 | 2013 | 340 | 0.140 |
Why?
| | Receptors, Androgen | 2 | 2010 | 150 | 0.140 |
Why?
| | beta-Galactosidase | 1 | 1997 | 78 | 0.140 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 247 | 0.140 |
Why?
| | Cloning, Molecular | 2 | 2001 | 534 | 0.140 |
Why?
| | Nuclear Proteins | 3 | 2007 | 712 | 0.130 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2016 | 51 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2004 | 1569 | 0.130 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2016 | 67 | 0.120 |
Why?
| | Colchicine | 2 | 2006 | 23 | 0.120 |
Why?
| | Fungi | 3 | 2011 | 144 | 0.120 |
Why?
| | Transcription Factors | 5 | 2016 | 1718 | 0.120 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 2 | 1993 | 145 | 0.120 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 1995 | 11 | 0.120 |
Why?
| | Plasmids | 2 | 1993 | 360 | 0.120 |
Why?
| | HL-60 Cells | 3 | 2001 | 34 | 0.120 |
Why?
| | HeLa Cells | 5 | 1997 | 633 | 0.120 |
Why?
| | Anthracenes | 2 | 2007 | 31 | 0.110 |
Why?
| | COS Cells | 4 | 2000 | 188 | 0.110 |
Why?
| | Cell Cycle | 3 | 2007 | 601 | 0.110 |
Why?
| | Gene Expression | 2 | 2005 | 1500 | 0.110 |
Why?
| | Microbial Sensitivity Tests | 6 | 2013 | 357 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2001 | 1163 | 0.110 |
Why?
| | Trans-Activators | 1 | 1997 | 398 | 0.110 |
Why?
| | Antiviral Agents | 2 | 2012 | 738 | 0.110 |
Why?
| | Trichothecenes | 2 | 2011 | 4 | 0.110 |
Why?
| | Lipids | 1 | 1998 | 665 | 0.110 |
Why?
| | Isocoumarins | 1 | 2013 | 1 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2001 | 2894 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 1993 | 664 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2013 | 28 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 1 | 1997 | 647 | 0.100 |
Why?
| | Aldehydes | 3 | 1999 | 145 | 0.100 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2013 | 5 | 0.100 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 10 | 0.100 |
Why?
| | Apoptosis | 4 | 2010 | 2552 | 0.100 |
Why?
| | Ascomycota | 1 | 2013 | 31 | 0.100 |
Why?
| | Drug Stability | 3 | 2009 | 167 | 0.100 |
Why?
| | Structure-Activity Relationship | 5 | 2012 | 570 | 0.100 |
Why?
| | Herb-Drug Interactions | 2 | 2009 | 4 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 48 | 0.100 |
Why?
| | Anthelmintics | 1 | 2012 | 11 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2016 | 1396 | 0.100 |
Why?
| | Disulfides | 1 | 2012 | 107 | 0.090 |
Why?
| | Monocytes | 1 | 1995 | 563 | 0.090 |
Why?
| | Anthraquinones | 1 | 2011 | 11 | 0.090 |
Why?
| | Xanthones | 1 | 2011 | 6 | 0.090 |
Why?
| | Drug Antagonism | 2 | 2001 | 10 | 0.090 |
Why?
| | Depsipeptides | 1 | 2011 | 14 | 0.090 |
Why?
| | Zearalenone | 1 | 2011 | 2 | 0.090 |
Why?
| | Cyanobacteria | 1 | 2012 | 56 | 0.090 |
Why?
| | Cyclin-Dependent Kinases | 3 | 2008 | 132 | 0.090 |
Why?
| | Hepacivirus | 1 | 2012 | 260 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 141 | 0.090 |
Why?
| | Lactones | 1 | 2011 | 56 | 0.090 |
Why?
| | Macrocyclic Compounds | 1 | 2010 | 9 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2010 | 184 | 0.080 |
Why?
| | Piperazines | 1 | 2012 | 350 | 0.080 |
Why?
| | Melanoma, Experimental | 1 | 1990 | 114 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 3 | 1997 | 345 | 0.080 |
Why?
| | Base Sequence | 6 | 1999 | 2179 | 0.080 |
Why?
| | Leukemia | 2 | 2001 | 238 | 0.080 |
Why?
| | Ginkgo biloba | 1 | 2009 | 8 | 0.080 |
Why?
| | Animals | 20 | 2012 | 36836 | 0.080 |
Why?
| | Recombinant Proteins | 4 | 2009 | 1350 | 0.080 |
Why?
| | Amino Acid Sequence | 4 | 2001 | 2138 | 0.080 |
Why?
| | Acclimatization | 1 | 1990 | 177 | 0.080 |
Why?
| | Echium | 1 | 2008 | 1 | 0.080 |
Why?
| | Pyrrolizidine Alkaloids | 1 | 2008 | 7 | 0.080 |
Why?
| | Plant Preparations | 1 | 2009 | 36 | 0.080 |
Why?
| | Warfarin | 1 | 2009 | 151 | 0.070 |
Why?
| | Glutathione Transferase | 2 | 1999 | 105 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 449 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 136 | 0.070 |
Why?
| | Mercuric Chloride | 1 | 1988 | 2 | 0.070 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 161 | 0.070 |
Why?
| | Microsomes | 1 | 1988 | 33 | 0.070 |
Why?
| | Epoxide Hydrolases | 1 | 1988 | 13 | 0.070 |
Why?
| | Protective Agents | 1 | 2008 | 41 | 0.070 |
Why?
| | Quaternary Ammonium Compounds | 2 | 1998 | 52 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2012 | 613 | 0.070 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 1998 | 54 | 0.070 |
Why?
| | Immunoconjugates | 1 | 2009 | 114 | 0.070 |
Why?
| | Simaroubaceae | 1 | 2007 | 1 | 0.070 |
Why?
| | Hot Temperature | 1 | 1990 | 390 | 0.070 |
Why?
| | Hepatocytes | 1 | 2009 | 220 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 65 | 0.070 |
Why?
| | Monosaccharides | 1 | 2007 | 12 | 0.070 |
Why?
| | Pharmacokinetics | 1 | 2007 | 29 | 0.070 |
Why?
| | Phosphorylation | 5 | 2016 | 1758 | 0.070 |
Why?
| | Herpesvirus 8, Human | 1 | 2007 | 65 | 0.070 |
Why?
| | Dendrimers | 1 | 2006 | 17 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 254 | 0.070 |
Why?
| | DNA, Neoplasm | 2 | 2001 | 164 | 0.070 |
Why?
| | Blotting, Western | 5 | 2008 | 1225 | 0.060 |
Why?
| | Genes | 1 | 1987 | 230 | 0.060 |
Why?
| | Anticarcinogenic Agents | 1 | 2007 | 77 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 288 | 0.060 |
Why?
| | Magnetic Resonance Spectroscopy | 4 | 2012 | 610 | 0.060 |
Why?
| | Flavones | 1 | 2006 | 10 | 0.060 |
Why?
| | Calendula | 1 | 2006 | 1 | 0.060 |
Why?
| | Case Management | 1 | 2006 | 66 | 0.060 |
Why?
| | Candida albicans | 3 | 2013 | 54 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1430 | 0.060 |
Why?
| | Microsomes, Liver | 3 | 2012 | 86 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 1987 | 142 | 0.060 |
Why?
| | Patient Dropouts | 1 | 2006 | 67 | 0.060 |
Why?
| | Purines | 1 | 2007 | 176 | 0.060 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2008 | 366 | 0.060 |
Why?
| | Models, Biological | 3 | 2008 | 1773 | 0.060 |
Why?
| | Chromatography, Affinity | 2 | 1997 | 88 | 0.060 |
Why?
| | Cell Growth Processes | 1 | 2005 | 52 | 0.060 |
Why?
| | Asteraceae | 1 | 2005 | 18 | 0.060 |
Why?
| | Genetic Variation | 1 | 1990 | 985 | 0.060 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2005 | 38 | 0.060 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1089 | 0.060 |
Why?
| | Alkaloids | 1 | 2005 | 30 | 0.060 |
Why?
| | Protein Binding | 3 | 2001 | 2216 | 0.060 |
Why?
| | Hypersensitivity, Delayed | 1 | 2004 | 28 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 1993 | 1455 | 0.060 |
Why?
| | Anticoagulants | 1 | 2009 | 662 | 0.060 |
Why?
| | Diospyros | 1 | 2004 | 1 | 0.060 |
Why?
| | Societies, Pharmaceutical | 1 | 2004 | 21 | 0.060 |
Why?
| | Naphthoquinones | 1 | 2004 | 19 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2006 | 1044 | 0.060 |
Why?
| | Liver | 2 | 2007 | 1940 | 0.060 |
Why?
| | Methylation | 2 | 2016 | 230 | 0.060 |
Why?
| | Taxus | 1 | 2004 | 1 | 0.060 |
Why?
| | Camptotheca | 1 | 2004 | 1 | 0.060 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2004 | 17 | 0.050 |
Why?
| | Carcinoma | 1 | 2006 | 238 | 0.050 |
Why?
| | Pharmaceutical Services | 1 | 2004 | 83 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2004 | 179 | 0.050 |
Why?
| | Leucine Zippers | 2 | 1993 | 17 | 0.050 |
Why?
| | Cell Survival | 4 | 2012 | 1116 | 0.050 |
Why?
| | Stereoisomerism | 3 | 2009 | 96 | 0.050 |
Why?
| | Proteins | 2 | 2000 | 1009 | 0.050 |
Why?
| | History, 20th Century | 1 | 2004 | 323 | 0.050 |
Why?
| | Patient Selection | 1 | 2006 | 691 | 0.050 |
Why?
| | Patient Compliance | 1 | 2006 | 577 | 0.050 |
Why?
| | Cell Proliferation | 4 | 2012 | 2476 | 0.050 |
Why?
| | Phloroglucinol | 1 | 2001 | 1 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2012 | 71 | 0.050 |
Why?
| | Bridged Bicyclo Compounds | 1 | 2001 | 12 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2001 | 41 | 0.050 |
Why?
| | Cytochrome P-450 CYP2C9 | 2 | 2012 | 20 | 0.050 |
Why?
| | Male | 14 | 2016 | 67305 | 0.050 |
Why?
| | Plastids | 1 | 2001 | 2 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2006 | 739 | 0.050 |
Why?
| | Eubacterium | 1 | 2001 | 3 | 0.050 |
Why?
| | Peptide Fragments | 2 | 1997 | 705 | 0.040 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 2011 | 86 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2001 | 88 | 0.040 |
Why?
| | DNA, Single-Stranded | 2 | 1993 | 118 | 0.040 |
Why?
| | Cell Nucleus | 3 | 2010 | 617 | 0.040 |
Why?
| | Carcinogens | 1 | 2001 | 124 | 0.040 |
Why?
| | Catalysis | 1 | 2001 | 307 | 0.040 |
Why?
| | Escherichia coli | 3 | 1993 | 807 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 385 | 0.040 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2000 | 72 | 0.040 |
Why?
| | Pharmacogenetics | 1 | 2001 | 179 | 0.040 |
Why?
| | Photosynthesis | 1 | 2001 | 103 | 0.040 |
Why?
| | Family Practice | 1 | 2004 | 462 | 0.040 |
Why?
| | Detergents | 1 | 2000 | 44 | 0.040 |
Why?
| | Kidney | 1 | 1988 | 1467 | 0.040 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2013 | 234 | 0.040 |
Why?
| | Glycosides | 2 | 2013 | 36 | 0.040 |
Why?
| | Biocompatible Materials | 2 | 2006 | 423 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2000 | 123 | 0.040 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 434 | 0.040 |
Why?
| | Esters | 1 | 2000 | 76 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2004 | 760 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2011 | 155 | 0.040 |
Why?
| | Cation Exchange Resins | 1 | 1998 | 7 | 0.040 |
Why?
| | DNA Damage | 1 | 2001 | 420 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2011 | 180 | 0.040 |
Why?
| | Response Elements | 1 | 1999 | 91 | 0.040 |
Why?
| | Carcinoma, Hepatocellular | 2 | 1999 | 361 | 0.040 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1998 | 91 | 0.040 |
Why?
| | Thymidine | 2 | 1995 | 60 | 0.040 |
Why?
| | Freezing | 1 | 1998 | 90 | 0.040 |
Why?
| | DNA Replication | 2 | 1997 | 238 | 0.040 |
Why?
| | Gentamicins | 1 | 1998 | 54 | 0.040 |
Why?
| | Arginine | 1 | 2000 | 271 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor Proteins | 2 | 2008 | 7 | 0.040 |
Why?
| | Polyesters | 1 | 1998 | 76 | 0.040 |
Why?
| | Saccharomyces cerevisiae | 3 | 2009 | 556 | 0.040 |
Why?
| | Mass Screening | 1 | 2006 | 1266 | 0.040 |
Why?
| | Cell Division | 2 | 1997 | 796 | 0.040 |
Why?
| | Trehalose | 1 | 1997 | 32 | 0.040 |
Why?
| | Drug Costs | 1 | 1998 | 106 | 0.030 |
Why?
| | Malondialdehyde | 1 | 1997 | 29 | 0.030 |
Why?
| | Plant Bark | 2 | 2009 | 11 | 0.030 |
Why?
| | Scattering, Radiation | 1 | 1997 | 101 | 0.030 |
Why?
| | Enzyme Stability | 1 | 1997 | 70 | 0.030 |
Why?
| | Aspergillus niger | 2 | 2009 | 7 | 0.030 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 1997 | 37 | 0.030 |
Why?
| | Indonesia | 2 | 2009 | 23 | 0.030 |
Why?
| | Phosphatidylethanolamines | 1 | 1997 | 77 | 0.030 |
Why?
| | Freeze Drying | 1 | 1997 | 84 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-myb | 1 | 1997 | 10 | 0.030 |
Why?
| | Sucrose | 1 | 1997 | 110 | 0.030 |
Why?
| | Histone Deacetylase 2 | 1 | 2016 | 10 | 0.030 |
Why?
| | Dimerization | 1 | 1997 | 198 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 1997 | 153 | 0.030 |
Why?
| | Histone Deacetylase 1 | 1 | 2016 | 25 | 0.030 |
Why?
| | Signal Transduction | 1 | 2010 | 5077 | 0.030 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 31 | 0.030 |
Why?
| | Protein Conformation | 2 | 1997 | 933 | 0.030 |
Why?
| | Binding Sites | 2 | 1997 | 1301 | 0.030 |
Why?
| | Sequence Deletion | 1 | 1997 | 183 | 0.030 |
Why?
| | Enzyme Activation | 3 | 2007 | 810 | 0.030 |
Why?
| | KB Cells | 2 | 2007 | 4 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-jun | 2 | 1993 | 55 | 0.030 |
Why?
| | Cytoplasm | 2 | 2008 | 272 | 0.030 |
Why?
| | Precipitin Tests | 2 | 1997 | 100 | 0.030 |
Why?
| | Jordan | 2 | 2006 | 3 | 0.030 |
Why?
| | Artemia | 2 | 2006 | 8 | 0.030 |
Why?
| | Breast Neoplasms | 2 | 2006 | 2234 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 346 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-fos | 2 | 1993 | 185 | 0.030 |
Why?
| | Butyric Acid | 1 | 1995 | 7 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1684 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1995 | 150 | 0.030 |
Why?
| | Time Factors | 3 | 2008 | 6808 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 1998 | 362 | 0.030 |
Why?
| | Light | 1 | 1997 | 378 | 0.030 |
Why?
| | United States | 2 | 2004 | 14682 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1995 | 268 | 0.030 |
Why?
| | Kinetics | 1 | 1997 | 1664 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 1997 | 1059 | 0.030 |
Why?
| | Bacteriophage T7 | 1 | 1993 | 5 | 0.030 |
Why?
| | Female | 8 | 2013 | 72785 | 0.030 |
Why?
| | DNA, Recombinant | 1 | 1993 | 47 | 0.030 |
Why?
| | Protein Sorting Signals | 1 | 1993 | 20 | 0.030 |
Why?
| | Adenovirus E1A Proteins | 1 | 1993 | 12 | 0.030 |
Why?
| | Glioblastoma | 2 | 2007 | 343 | 0.030 |
Why?
| | DNA, Superhelical | 1 | 1993 | 11 | 0.030 |
Why?
| | Kidney Tubules | 1 | 1994 | 117 | 0.030 |
Why?
| | Nickel | 1 | 1993 | 62 | 0.030 |
Why?
| | Haemonchus | 1 | 2012 | 1 | 0.020 |
Why?
| | Mice | 4 | 2012 | 17758 | 0.020 |
Why?
| | Rats | 4 | 1999 | 5639 | 0.020 |
Why?
| | Phenotype | 1 | 2001 | 3189 | 0.020 |
Why?
| | Glucose | 1 | 1997 | 1019 | 0.020 |
Why?
| | Depression | 1 | 2001 | 1397 | 0.020 |
Why?
| | Optical Rotation | 1 | 2011 | 1 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1993 | 374 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 657 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2012 | 127 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 2011 | 54 | 0.020 |
Why?
| | Hydroxybenzoates | 1 | 2011 | 10 | 0.020 |
Why?
| | Resorcinols | 1 | 2011 | 5 | 0.020 |
Why?
| | Histones | 1 | 2016 | 636 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2013 | 476 | 0.020 |
Why?
| | Blood Proteins | 1 | 1993 | 252 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 1994 | 480 | 0.020 |
Why?
| | Epitopes | 1 | 1993 | 480 | 0.020 |
Why?
| | Daunorubicin | 1 | 1990 | 26 | 0.020 |
Why?
| | Caspase 8 | 1 | 2010 | 48 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1993 | 2605 | 0.020 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 30 | 0.020 |
Why?
| | Protein Kinases | 1 | 1992 | 319 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1998 | 2831 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1990 | 105 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2010 | 87 | 0.020 |
Why?
| | Phosphates | 1 | 1991 | 182 | 0.020 |
Why?
| | Aporphines | 1 | 2009 | 1 | 0.020 |
Why?
| | Micrococcus luteus | 1 | 2009 | 3 | 0.020 |
Why?
| | Hydroxylation | 1 | 2009 | 39 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2010 | 114 | 0.020 |
Why?
| | Placebos | 1 | 2010 | 199 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2010 | 91 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2009 | 90 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 597 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2012 | 362 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 410 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2009 | 189 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2008 | 53 | 0.020 |
Why?
| | Mycobacterium tuberculosis | 1 | 2012 | 312 | 0.020 |
Why?
| | Acrolein | 2 | 1999 | 23 | 0.020 |
Why?
| | Cell Line | 2 | 1994 | 2838 | 0.020 |
Why?
| | Doxorubicin | 1 | 1990 | 362 | 0.020 |
Why?
| | cdc25 Phosphatases | 1 | 2008 | 15 | 0.020 |
Why?
| | Isomerism | 1 | 2008 | 56 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 194 | 0.020 |
Why?
| | Microcirculation | 1 | 2008 | 146 | 0.020 |
Why?
| | Bacteria | 2 | 2005 | 854 | 0.020 |
Why?
| | Mycobacterium | 1 | 2009 | 108 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 167 | 0.020 |
Why?
| | Metallothionein | 1 | 1988 | 25 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2008 | 145 | 0.020 |
Why?
| | Enzyme Induction | 1 | 1988 | 90 | 0.020 |
Why?
| | Cyclins | 1 | 2008 | 91 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 1988 | 362 | 0.020 |
Why?
| | Leukemia P388 | 1 | 2007 | 7 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 1988 | 264 | 0.020 |
Why?
| | Dominican Republic | 1 | 2007 | 24 | 0.020 |
Why?
| | Cells, Cultured | 3 | 1994 | 4192 | 0.020 |
Why?
| | Amino Acids | 1 | 1991 | 497 | 0.020 |
Why?
| | Peptides | 1 | 2013 | 981 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1995 | 1982 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 1987 | 15 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 226 | 0.020 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2007 | 49 | 0.020 |
Why?
| | Fluorescence | 1 | 2007 | 160 | 0.020 |
Why?
| | Capsules | 1 | 2006 | 38 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 696 | 0.020 |
Why?
| | Biological Assay | 1 | 2007 | 123 | 0.020 |
Why?
| | Antigens, Viral | 1 | 2007 | 181 | 0.020 |
Why?
| | Species Specificity | 1 | 1988 | 586 | 0.020 |
Why?
| | Blotting, Northern | 2 | 1998 | 200 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 388 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 245 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1269 | 0.020 |
Why?
| | Glutathione | 1 | 1988 | 356 | 0.020 |
Why?
| | Caspases | 1 | 2007 | 247 | 0.020 |
Why?
| | Amphotericin B | 1 | 2005 | 31 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 543 | 0.020 |
Why?
| | Plant Leaves | 1 | 2007 | 147 | 0.020 |
Why?
| | Plant Components, Aerial | 1 | 2005 | 3 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 194 | 0.020 |
Why?
| | Cell Death | 1 | 2007 | 372 | 0.020 |
Why?
| | Biological Transport | 1 | 2006 | 416 | 0.020 |
Why?
| | Drosophila | 1 | 1987 | 151 | 0.020 |
Why?
| | Culture | 1 | 2006 | 125 | 0.010 |
Why?
| | Telephone | 1 | 2006 | 170 | 0.010 |
Why?
| | Social Work | 1 | 2006 | 85 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 975 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2010 | 1982 | 0.010 |
Why?
| | Cognition Disorders | 1 | 2009 | 495 | 0.010 |
Why?
| | Coumarins | 1 | 2004 | 18 | 0.010 |
Why?
| | Pilot Projects | 1 | 2010 | 1693 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1180 | 0.010 |
Why?
| | Fluorouracil | 1 | 2004 | 210 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2004 | 389 | 0.010 |
Why?
| | Methotrexate | 1 | 2004 | 260 | 0.010 |
Why?
| | Models, Molecular | 1 | 2008 | 1569 | 0.010 |
Why?
| | Poverty | 1 | 2006 | 520 | 0.010 |
Why?
| | Social Support | 1 | 2006 | 616 | 0.010 |
Why?
| | 14-3-3 Proteins | 1 | 2000 | 18 | 0.010 |
Why?
| | Cations | 1 | 2000 | 84 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3264 | 0.010 |
Why?
| | Ethacrynic Acid | 1 | 1998 | 1 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 791 | 0.010 |
Why?
| | Absorption | 1 | 1998 | 63 | 0.010 |
Why?
| | Chemistry, Pharmaceutical | 1 | 1998 | 105 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 1076 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 211 | 0.010 |
Why?
| | Immune Sera | 1 | 1997 | 88 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 2006 | 1235 | 0.010 |
Why?
| | Oxidants | 1 | 1997 | 111 | 0.010 |
Why?
| | Immunoblotting | 1 | 1997 | 306 | 0.010 |
Why?
| | Osteomyelitis | 1 | 1998 | 131 | 0.010 |
Why?
| | Adult | 1 | 1999 | 37626 | 0.010 |
Why?
| | Rabbits | 1 | 1997 | 792 | 0.010 |
Why?
| | Infant | 1 | 2010 | 9395 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 10997 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2006 | 7593 | 0.010 |
Why?
| | Growth Substances | 1 | 1994 | 147 | 0.010 |
Why?
| | Activating Transcription Factors | 1 | 1993 | 2 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2489 | 0.010 |
Why?
| | Epithelium | 1 | 1994 | 311 | 0.010 |
Why?
| | Baculoviridae | 1 | 1992 | 44 | 0.010 |
Why?
| | Zinc Fingers | 1 | 1992 | 50 | 0.010 |
Why?
| | Moths | 1 | 1992 | 45 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1992 | 182 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2486 | 0.010 |
Why?
| | Swine | 1 | 1994 | 773 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1992 | 317 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 21380 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 1992 | 465 | 0.010 |
Why?
| | Zinc | 1 | 1993 | 297 | 0.010 |
Why?
| | Child | 1 | 2010 | 21816 | 0.010 |
Why?
| | Epithelial Cells | 1 | 1994 | 1094 | 0.000 |
Why?
| | Aged | 1 | 2006 | 23800 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 33225 | 0.000 |
Why?
| | Mutation | 1 | 1993 | 3947 | 0.000 |
Why?
|
|
Kroll's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|